Advertisement

Advertisement

2019 Genitourinary Cancers Symposium

Prostate Cancer

ARAMIS Trial Reports Darolutamide Improves Outcomes in High-Risk Nonmetastatic Prostate Cancer

Darolutamide—an investigational androgen receptor inhibitor—significantly improved metastasis-free survival in men with high-risk nonmetastatic castration-resistant prostate cancer vs placebo in the l...

Prostate Cancer

Radioligand Therapy Achieves Responses in Metastatic Prostate Cancer

In a prospective, single-center, single-arm phase II trial reported at the 2019 Genitourinary Cancers Symposium, a novel approach using a tumor-specific radioligand therapy that binds to prostate-spec...

Kidney Cancer

Pembrolizumab/Axitinib Combination Improves Outcomes vs Sunitinib in Kidney Cancer

The checkpoint inhibitor pembrolizumab plus the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor axitinib significantly improved overall survival, progression-free survival, and obj...

kidney cancer
immunotherapy

2019 GU Cancers Symposium: First-Line Pembrolizumab Plus Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma

As reported at the 2019 Genitourinary Cancers Symposium (Abstract 543) and in The New England Journal of Medicine, Rini et al found significant benefits in overall and progression-free survival with t...

prostate cancer
immunotherapy

Sumit K. Subudhi, MD, PhD, on Prostate Cancer: Results From the CheckMate 650 Trial on Nivolumab and Ipilimumab

Sumit K. Subudhi, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the initial results from a phase II study of nivolumab plus ipilimumab in the treatment of metastatic castrat...

Sumanta K. Pal, MD, on Clinical Cancer Advances: The 14th Annual Report

Sumanta K. Pal, MD, of City of Hope, who served as a Co-Executive Editor of the 2019 publication Clinical Cancer Advances, discusses progress made during the past year in research and policy. The repo...

kidney cancer

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses current models used to estimate the risk of recurrence as well as genomic data that could help pinpoint individual tumor ...

prostate cancer

Howard I. Scher, MD, on Prostate Cancer: Circulating Tumor Cells as a Surrogate Endpoint for Survival

Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials on metastatic castration-re...

solid tumors

Craig R. Nichols, MD, on Testicular Cancer Cases: Should They Be Discussed With High-Volume Centers?

Craig R. Nichols, MD, of the Testicular Cancer Commons and the SWOG Group Chair's Office, discusses the superior outcomes obtained at high-volume centers, the impracticality of referring all patients ...

bladder cancer

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel

Thomas Powles, MD, PhD, of Queen Mary University of London, discusses phase III study findings on ramucirumab plus docetaxel vs placebo plus docetaxel in patients with advanced platinum-refractory uro...

kidney cancer
immunotherapy

Rana R. McKay, MD, on Renal Cell Carcinoma: Results From a Trial on Atezolizumab and Bevacizumab

Rana R. McKay, MD, of the University of California, San Diego, discusses phase II study findings on atezolizumab and bevacizumab in non–clear cell renal cell carcinoma and clear cell renal cell carcin...

bladder cancer

Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?

Jason A. Efstathiou, MD, DPhil, of Massachusetts General Hospital, discusses the debate over treating muscle-invasive bladder cancer with radical cystectomy vs trimodality therapy.

solid tumors

Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin

Stefanie C. Fischer, MD, of Manchester Cancer Research Centre and The Christie NHS Foundation Trust, discusses an international retrospective analysis of the rare clinical scenario of men relapsing af...

kidney cancer

Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses phase III findings on a comparison of tivozanib and sorafenib in patients with refractory advanced renal cell carcinoma (...

prostate cancer
symptom management

Silke Gillessen, MD, on Prostate Cancer: Results From the REDUSE Trial on Denosumab

Silke Gillessen, MD, of Cantonal Hospital St. Gallen, discusses data from a phase III study on the incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosuma...

prostate cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the ARAMIS Trial on Darolutamide

Karim Fizazi, MD, PhD, of the University of Paris-Sud and Gustave Roussy, discusses study findings on the efficacy and safety of darolutamide in men with nonmetastatic castration-resistant prostate ca...

kidney cancer

Ignacio Duran, MD, PhD, on Renal Cell Carcinoma: Results From the METEOR Trial on Cabozantinib vs Everolimus

Ignacio Duran, MD, PhD, of the Hospital Universitario Marqués de Valdecilla, discusses an overall survival analysis of the phase III METEOR trial of cabozantinib vs everolimus in advanced renal cell c...

kidney cancer
immunotherapy

Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Results From the NIVOREN GETUG-AFU 26 Study on Nivolumab

Laurence Albiges, MD, PhD, of Gustave Roussy, discusses findings on the safety and efficacy of nivolumab used in a “real world” prospective study on metastatic renal cell carcinoma (mRCC). This resear...

bladder cancer

Brian C. Baumann, MD, on Bladder Cancer: Trial Results on Adjuvant Chemoradiotherapy vs Adjuvant Radiotherapy Alone

Brian C. Baumann, MD, of Washington University School of Medicine, discusses phase III study findings on adjuvant sequential chemotherapy plus radiotherapy vs adjuvant radiotherapy alone for locally a...

prostate cancer

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Nicholas J. van As, MD, of The Royal Marsden NHS Foundation Trust, discusses an analysis of acute toxicity in the PACE-B study, which compared stereotactic body radiotherapy with conventionally fracti...

kidney cancer

2019 GU Cancers Symposium: TIVO-3: Tivozanib vs Sorafenib in Refractory Advanced Renal Cell Carcinoma

The TIVO-3 trial was conducted to confirm progression-free survival results from the TIVO-1 trial, which found an improvement in median progression-free survival in patients with metastatic renal...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Trial Results on Avelumab Plus Axitinib vs Sunitinib

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses a subgroup analysis from the JAVELIN Renal 101 study on outcomes for avelumab plus axitinib vs sunitinib in advanced renal cell carcino...

prostate cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial on Abiraterone Acetate Plus Prednisone

Karim Fizazi, MD, PhD, of the University of Paris-Sud and Gustave Roussy, discusses final phase III findings on men with newly diagnosed, high-risk, metastatic, castration-naive prostate cancer who we...

kidney cancer
immunotherapy

Brian I. Rini, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Results From the KEYNOTE-426 Trial on Pembrolizumab Plus Axitinib vs Sunitinib

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and Thomas Powles, MD, PhD, of Queen Mary University of London, discuss their study findings on pembrolizumab plus axitinib vs suni...

prostate cancer

2019 GU Cancers Symposium: ARAMIS: Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

In the phase III ARAMIS trial reported by Fizazi et al at the 2019 Genitourinary Cancers Symposium (Abstract 140) and simultaneously published in The New England Journal of Medicine, researchers found...

prostate cancer
immunotherapy

2019 GU Cancers Symposium: CheckMate 650: Nivolumab and Ipilimumab in Metastatic, Castration-Resistant Prostate Cancer

Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after treatment with hormonal therapy and chemotherapy has not been...

kidney cancer
immunotherapy

2019 GU Cancers Symposium: JAVELIN Renal 101: Avelumab Plus Axitinib vs Sunitinib for Advanced Kidney Cancer

A combination of two drugs could become a new standard first-line treatment for patients with metastatic kidney cancer, according to results from the JAVELIN Renal 101 trial presented at the 2019 Geni...

kidney cancer
immunotherapy

2019 GU Cancers Symposium: KEYNOTE-426: Pembrolizumab Plus Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma

Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of pembrolizumab and axitinib extended both overall survival (OS) and progression-free...

prostate cancer
issues in oncology

2019 GU Cancers Symposium: Study Evaluates Survival by Race in Metastatic Castration-Resistant Prostate Cancer

A large, retrospective study analyzing 5 years of data from the Veterans Health Administration (VHA) found that African American men with chemotherapy-naive, metastatic, castration-resistant prostate ...

prostate cancer

2019 GU Cancers Symposium: Small Trial of LuPSMA in PSMA-Positive, Metastatic, Castration-Resistant Prostate Cancer

A single-arm, phase II trial in men with prostate-specific membrane antigen (PSMA)-positive, metastatic, castration-resistant prostate cancer that progressed despite standard therapies found that a ma...

Advertisement

Advertisement



;
Advertisement